Page 70 - BSAVA Guide to Pain Management in Small Animal Practice
P. 70

5  |  Pharmacological treatment of pain



        VetBooks.ir  Other routes                  achieved only with pre-incisional administration
                                                    Chahar and Cummings,   1 ; Viscusi et al.,
             Other commonly used routes of administration
                                                     14;  oshi et al.,   1 ; Aratana,   16; Lascelles
             for local anaesthetics are intra-articular,
             intrapleural and intraperitoneal.  hile there is   and  irkby Shaw,   16 .
             little concern in terms of systemic toxicity after
             intra-articular administration, the absorption   Intravenous lidocaine
             rate from the pleural and peritoneal space is   Unlike other local anaesthetics, lidocaine can
             signi cant, resulting in potentially toxic   be safely administered as an intravenous
             concentrations if large doses are administered.   infusion due to its limited toxicity, at least in
             In cats, intraperitoneal administration of   mg   dogs. In cats, the margin of safety is smaller;
             kg bupivacaine  .   did not result in systemic   therefore, there is a greater risk of side e ects.
             toxicity with peak plasma concentration    hile its use as an antiarrhythmic or its role in
             occurring    minutes after administration, and   ischaemic reperfusion injury and shock are not
             had an elimination half life of approximately     the subject of this handbook, intravenous
             hours, suggesting that this dose and route of   lidocaine infusion can be used to provide
             administration for bupivacaine may be safe, at   perioperative analgesia in the hospitalized
             least in the presence of a normal peritoneum.   animal. Lidocaine s e cacy in treating
             The major concern after intra-articular   neuropathic pain has been reported in humans
             administration is chondrotoxicity. Studies in   since the 198 s, in particular to treat post
             humans have demonstrated that this risk is   herpetic, diabetic and chemotherapy-induced
             signi cant for repeated administrations and   neuropathy. Its e cacy is supported by a
             infusions, while it is less clinically relevant after   Cochrane review (Kranke et al.,   1  .  he most
             single administration. In vitro studies have   plausible mechanism of action of lidocaine in
             demonstrated dose- and time-dependent   this setting is the blockade of sodium channels,
             chondrotoxicity for all local anaesthetics. A   reducing ectopic  ring of damaged nerves and
             study in dogs has demonstrated chondrotoxicity   neurons. In ured  bres and neurons are more
             for both lidocaine and bupivacaine after single   sensitive to lidocaine at low doses because of
             administration with steroids in the shoulder joint   the characteristic upregulation of sodium
             (Aguirre et al.,   1 ;  i Salvo et al.,   14,   1 ;   channels observed after the injury. The
             Sherman et al.,   1  .                response to lidocaine administration may be
                                                   variable, depending on the type of sodium
             Liposomal bupivacaine                 channel that is upregulated, as lidocaine is
             A liposomal bupivacaine formulation has been   more e ective in blocking tetrodotoxin resistant
             licensed by the US Food and Drug      sodium channels compared with tetrodotoxin-
             Administration for use in dogs undergoing   sensitive ones, with the former being mostly
             cranial cruciate surgery. Liposomal bupivacaine   upregulated in nerves after injury. The analgesic
             has been licensed for use in humans since   11,   and minimum alveolar concentration (MAC)
             as a single dose local in ltration analgesic   sparing e ect of systemic lidocaine has been
             techni ue. After in ltration in soft tissues at the   demonstrated in the dog, although currently
             end of surgery, bupivacaine is slowly released   there are no systematic studies investigating its
             from the vesicular liposomes, resulting in   e cacy in treating neuropathic pain syndromes,
             sustained analgesia for several days. In practical   and the current evidence is limited to case
             terms this is equivalent to continuous infusion   reports, expert opinion, and the known e cacy
             of local analgesics using a wound soaking   in human beings. Unfortunately, the use of
             catheter, but without the possible catheter-  intravenous lidocaine infusions to treat
             related complications. This method of   neuropathic pain is limited to the hospital
             administration does not allow the exploitation of   setting; until a few years ago, mexiletine was
             one of the most relevant advantages of local   available as an oral alternative to continue
             anaesthesia: preventive analgesia, which can be   therapy at home in dogs that had a positive

                                                                                     65



         Ch05 Pain Management.indd   65                                         19/12/2018   10:36
   65   66   67   68   69   70   71   72   73   74   75